Clinical effect of sotorasibu (AMG 510) in the treatment of KRAS G12C mutated lung cancer

Sotorasib is a first-in-class KRAS G12C selective inhibitor specifically targeted at patients with non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations. KRAS G12CMutation is one of the common driver gene mutations in lung cancer, and traditional targeted drugs have limited efficacy. Sotorasibirreversibly binds to KRAS G12C mutant protein and inhibits the downstream MAPK signaling pathway, thus blocking tumor cell proliferation and survival, providing new treatment options for these patients.

Clinical trials show that Sotorasibin patients with advanced NSCLC who have previously received standard treatment, the objective response rate (ORR) is approximately 36%-37%, and the median duration of response is approximately 10About 10 months. In most patients, tumor size reduction and symptom improvement can be observed within 33 months before treatment. The efficacy significantly improved the quality of life and disease control rate of patients with KRAS G12C mutation.

The median progression-free survival (PFS) of Sotorasib is approximately 6-7 months, and the median overall survival (OS) can reach more than 12 months. Despite the ideal efficacy, some patients will develop acquired resistance. Common mechanisms include activation of alternative signaling pathways (such as MET, EGFRamplification) or KRAS mutation subtype evolution. Therefore, the sustainability of efficacy depends on regular imaging monitoring and individualized treatment strategies.

In clinical practice, Sotorasib is mainly used for KRAS G12C-positive advanced NSCLC patients who have progressed after previous standard treatment (chemotherapy or immunotherapy). Patients should regularly monitor liver and kidney function and hematological indicators during medication, and pay attention to possible adverse reactions, such as mild to moderate diarrhea, elevated liver enzymes, or fatigue. Combining molecular testing and imaging follow-up, the efficacy can be reasonably evaluated, the treatment plan can be optimized, and the long-term survival and quality of life of patients can be improved.

Reference materials:https://www.drugs.com/